BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37791408)

  • 21. Physiologically-Based Pharmacokinetic Modeling for the Prediction of a Drug-Drug Interaction of Combined Effects on P-glycoprotein and Cytochrome P450 3A.
    Otsuka Y; Choules MP; Bonate PL; Komatsu K
    CPT Pharmacometrics Syst Pharmacol; 2020 Nov; 9(11):659-669. PubMed ID: 33030266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing major bleeding risk in atrial fibrillation patients concurrently taking non-vitamin K antagonist oral anticoagulants and antiepileptic drugs.
    Wang CL; Wu VC; Chang KH; Tu HT; Kuo CF; Huang YT; Chu PH; Kuo CC; Chang SH
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(3):147-154. PubMed ID: 31384926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparing the Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants and Warfarin in Elderly Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study.
    Chao TF; Chiang CE; Liao JN; Chen TJ; Lip GYH; Chen SA
    Chest; 2020 May; 157(5):1266-1277. PubMed ID: 31809694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation.
    Lee HF; Chan YH; Chang SH; Tu HT; Chen SW; Yeh YH; Wu LS; Kuo CF; Kuo CT; See LC
    J Am Heart Assoc; 2019 Mar; 8(5):e011112. PubMed ID: 30834802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation: Systematic review and meta-analysis.
    Kim IS; Kim HJ; Yu HT; Kim TH; Uhm JS; Kim JY; Joung B; Lee MH; Pak HN
    J Cardiol; 2019 Jun; 73(6):515-521. PubMed ID: 30770140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants.
    Chan YH; Lee HF; Li PR; Liu JR; Chao TF; Wu LS; Chang SH; Yeh YH; Kuo CT; See LC; Lip GYH
    Cardiovasc Diabetol; 2020 May; 19(1):63. PubMed ID: 32404168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of Incident Atrial Fibrillation and Subsequent Use of Oral Anticoagulants in Patients with Dementia.
    Tsai CT; Chan YH; Liao JN; Chen TJ; Lip GYH; Chen SA; Chao TF
    Thromb Haemost; 2024 Mar; 124(3):253-262. PubMed ID: 37776848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug Utilization Pattern of Oral Anticoagulants in Patients with Atrial Fibrillation: A Nationwide Population-Based Study in Korea.
    Lee MY; Han S; Bang OY; On YK; Jang SW; Han S; Ryu J; Park YJ; Kang S; Suh HS; Kim YH
    Adv Ther; 2022 Jul; 39(7):3112-3130. PubMed ID: 35524839
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fracture risks among patients with atrial fibrillation receiving different oral anticoagulants: a real-world nationwide cohort study.
    Huang HK; Liu PP; Hsu JY; Lin SM; Peng CC; Wang JH; Loh CH
    Eur Heart J; 2020 Mar; 41(10):1100-1108. PubMed ID: 32006423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis.
    Caldeira D; Rodrigues FB; Barra M; Santos AT; de Abreu D; Gonçalves N; Pinto FJ; Ferreira JJ; Costa J
    Heart; 2015 Aug; 101(15):1204-11. PubMed ID: 26037103
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?
    Hellwig T; Gulseth M
    Ann Pharmacother; 2013 Nov; 47(11):1478-87. PubMed ID: 24259602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
    Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding.
    Hanigan S; Das J; Pogue K; Barnes GD; Dorsch MP
    J Thromb Thrombolysis; 2020 May; 49(4):636-643. PubMed ID: 31925665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The optimal drug adherence to maximize the efficacy and safety of non-vitamin K antagonist oral anticoagulant in real-world atrial fibrillation patients.
    Kim D; Yang PS; Jang E; Yu HT; Kim TH; Uhm JS; Kim JY; Sung JH; Pak HN; Lee MH; Lip GYH; Joung B
    Europace; 2020 Apr; 22(4):547-557. PubMed ID: 31598651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of Osteoporosis in Patients With Atrial Fibrillation Using Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin.
    Huang HK; Liu PP; Hsu JY; Lin SM; Peng CC; Wang JH; Yeh JI; Loh CH
    J Am Heart Assoc; 2020 Jan; 9(2):e013845. PubMed ID: 31918601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rivaroxaban Versus Apixaban for Stroke Prevention in Atrial Fibrillation: An Instrumental Variable Analysis of a Nationwide Cohort.
    Bonde AN; Martinussen T; Lee CJ; Lip GYH; Staerk L; Bang CN; Bhattacharya J; Gislason G; Torp-Pedersen C; Olesen JB; Hlatky MA
    Circ Cardiovasc Qual Outcomes; 2020 Apr; 13(4):e006058. PubMed ID: 32283966
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of developing diabetes in patients with atrial fibrillation taking non-vitamin K antagonist oral anticoagulants or warfarin: A nationwide cohort study.
    Huang HK; Liu PP; Lin SM; Hsu JY; Peng CC; Munir KM; Wu TY; Yeh JI; Loh CH; Tu YK
    Diabetes Obes Metab; 2021 Feb; 23(2):499-507. PubMed ID: 33140538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness and Safety of Contemporary Oral Anticoagulants Among Asians With Nonvalvular Atrial Fibrillation.
    Lee SR; Choi EK; Kwon S; Han KD; Jung JH; Cha MJ; Oh S; Lip GYH
    Stroke; 2019 Aug; 50(8):2245-2249. PubMed ID: 31208303
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Off-label dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation.
    Chan YH; Chao TF; Chen SW; Lee HF; Yeh YH; Huang YC; Chang SH; Kuo CT; Lip GYH; Chen SA
    Heart Rhythm; 2020 Dec; 17(12):2102-2110. PubMed ID: 32702416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Minimal Adherence Threshold to Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation to Reduce the Risk of Thromboembolism and Death: A Nationwide Cohort Study.
    Grymonprez M; Steurbaut S; Capiau A; Vauterin D; Van Vaerenbergh F; Mehuys E; Boussery K; De Backer TL; Lahousse L
    Cardiovasc Drugs Ther; 2023 Sep; ():. PubMed ID: 37707648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.